Company news
Cambium Bio Ltd news in 2026
Cambium Bio Ltd's news releases, calls and decks from 2026, newest first.
Quarterly Activities/Appendix 4C Cash Flow Report
October 28, 2026
Access Letter and Online Meeting Guide
October 7, 2026
Notice of Annual General Meeting and Proxy form
October 7, 2026
Proposed issue of securities - CMB
October 7, 2026
Corporate Presentation - September 2026
September 29, 2026
Date of AGM and Closing Date for Director Nominations
September 27, 2026
Notification of cessation of securities - CMB
September 23, 2026
Notification regarding unquoted securities - CMB
September 22, 2026
Cambium Bio Secures A$10.85 Million to Initiate Pivotal Phase 3 Trial of Elate Ocular®, a Potential First-in-Class Biologic for Dry Eye Disease
September 16, 2026
Cambium Bio Secures A$10.85 Million Funding Package
September 15, 2026
Proposed issue of securities - CMB
September 15, 2026
Notice of ceasing to be a substantial holder
September 15, 2026
Change in Substantial Holding
September 15, 2026
Update - Proposed issue of securities - CMB
September 1, 2026
Notification regarding unquoted securities - CMB
September 1, 2026
Proposed issue of securities - CMB
August 31, 2026
FY26 Appendix 4E and Annual Report
August 28, 2026
FY26 Appendix 4G and Corporate Governance Statement
August 28, 2026
Change in Company Secretary and Communication Person
August 26, 2026
Updated Securities Trading Policy
August 4, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
July 29, 2026
Cambium Bio Raises A$1.0 Million via Placement
July 21, 2026
FDA Confirms Single Pivotal Trial Pathway for Elate Ocular
April 23, 2026
Half Year Report and Accounts
February 19, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
January 22, 2026
Cambium Bio Secures A$2.4 Million Strategic Investment
January 19, 2026
Decks in 2026
- Investor Presentation (September 2026)
Investor deck · 29 slides · Sep 30, 2026